These results indicated that the low concentration of 10 μM EGCG that does not induce cellular toxicity, has a potential bioavailability towards chemoprevention and therapy through regulating ERα re-expression in ERα-negative breast cancer cells. Here, ESR1 is linked to breast carcinoma.